Item
Gender
text
C0079399 (UMLS CUI [1])
Age
Item
≥18 years of age
boolean
C0001779 (UMLS CUI [1])
Histological diagnosis of RCC | Histologicaldiagnosis of HCC | Histological diagnosis of GIST
Item
histological proof of rcc, hcc or gist
boolean
C0679557 (UMLS CUI [1,1])
C0007134 (UMLS CUI [1,2])
C0679557 (UMLS CUI [2,1])
C2239176 (UMLS CUI [2,2])
C0679557 (UMLS CUI [3,1])
C0238198 (UMLS CUI [3,2])
Oral adverse events due to mono therapy with sunitinib, sorafenib, pazopanib, temsirolimus, or everolimus at study entry
Item
oral adverse events > grade 0 due to sunitinib, sorafenib, pazopanib, temsirolimus, or everolimus in mono therapy at study entry
boolean
C1176020 (UMLS CUI [1,1])
C4763675 (UMLS CUI [1,2])
C0877248 (UMLS CUI [1,3])
C0442027 (UMLS CUI [1,4])
C1516119 (UMLS CUI [2,1])
C4763675 (UMLS CUI [2,2])
C0877248 (UMLS CUI [2,3])
C0442027 (UMLS CUI [2,4])
C2697888 (UMLS CUI [2,5])
C1831796 (UMLS CUI [3,1])
C4763675 (UMLS CUI [3,2])
C0877248 (UMLS CUI [3,3])
C0442027 (UMLS CUI [3,4])
C2697888 (UMLS CUI [3,5])
C1707080 (UMLS CUI [4,1])
C4763675 (UMLS CUI [4,2])
C0877248 (UMLS CUI [4,3])
C0442027 (UMLS CUI [4,4])
C2697888 (UMLS CUI [4,5])
C0541315 (UMLS CUI [5,1])
C4763675 (UMLS CUI [5,2])
C0877248 (UMLS CUI [5,3])
C0442027 (UMLS CUI [5,4])
C2697888 (UMLS CUI [5,5])
Written Informed Consent
Item
written informed consent
boolean
C0021430 (UMLS CUI [1])
ECOG Performance Status
Item
eastern co-operative oncology group (ecog) performance status ≤ 2
boolean
C1520224 (UMLS CUI [1])
Ability to perform oral rinsing
Item
able to perform oral rinsing
boolean
C0442027 (UMLS CUI [1,1])
C1882955 (UMLS CUI [1,2])
C0085732 (UMLS CUI [1,3])
Ability to complete Questionnaires (by themselves or with assistance)
Item
able to complete questionnaires by themselves or with assistance
boolean
C0034394 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C0085732 (UMLS CUI [1,3])
C1521721 (UMLS CUI [2])
Previous Systemic antineoplastic tretment
Item
any previous systemic antineoplastic treatment within 4 weeks of initiation of current targeted anticancer therapy
boolean
C0003392 (UMLS CUI [1,1])
C1515119 (UMLS CUI [1,2])
C0205156 (UMLS CUI [1,3])
Current combination of a cytotoxic chemotherapy to the antineoplastic treatment
Item
current antineoplastic combination with cytotoxic chemotherapy
boolean
C0677881 (UMLS CUI [1,1])
C0003392 (UMLS CUI [1,2])
C0205420 (UMLS CUI [1,3])
Condition that precludes oral rinsing
Item
physiologic condition that precludes the use of an oral rinse
boolean
C0012634 (UMLS CUI [1,1])
C0442027 (UMLS CUI [1,2])
C1882955 (UMLS CUI [1,3])
C1301624 (UMLS CUI [1,4])
Hypersensitivity to Caphosol Ingredients
Item
hypersensitivity to caphosol ingredients
boolean
C1170120 (UMLS CUI [1,1])
C1550600 (UMLS CUI [1,2])
C0020517 (UMLS CUI [1,3])
Palifermin | Oral Cryotherapy | low level laser therapy | Topical Steroids
Item
use of palifermin, oral cryotherapy, low level laser therapy, topical oral steroids within 3 weeks of current targeted anticancer therapy
boolean
C0677829 (UMLS CUI [1])
C0279027 (UMLS CUI [2])
C2064827 (UMLS CUI [3])
C0010408 (UMLS CUI [4,1])
C0442027 (UMLS CUI [4,2])
Oral abnormalities defines as base line oral assessment of NCI-CTCAE v4.0
Item
oral abnormalities defined as baseline oral assessment of nci-ctcae v4.0 grade > 0
boolean
C0026633 (UMLS CUI [1,1])
C3887242 (UMLS CUI [1,2])
Cytochrome P450 CYP3a4 Inhibitors, Irreversible | Cytochrome P450 CYP3a4 inducers, strong
Item
current use of agents that are known to be strong inducers or inhibitors of cyp3a4 that can not be stopped
boolean
C3850053 (UMLS CUI [1,1])
C0442821 (UMLS CUI [1,2])
C1272690 (UMLS CUI [1,3])
C3850041 (UMLS CUI [2,1])
C0442821 (UMLS CUI [2,2])
C1272690 (UMLS CUI [2,3])